Kallikrein Inhibitors

Plasma Kallikrein Inhibitor

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Lanadelumab-flyo, a plasma kallikrein inhibitor, is a non-plasma derived, recombinant, fully human, monoclonal antibody (IgG1/κ-light chain) produced in Chinese Hamster Ovary (CHO) cells. Based on the amino acid sequence, the molecular weight of the non-glycosylated lanadelumab-flyo is 146 kDa. The calculated molecular mass of the fully reduced light chain is 23 kDa. The calculated molecular mass of the fully reduced and non-glycosylated heavy chain is 49 kDa.</p><p>TAKHZYRO (lanadelumab-flyo) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous use.</p><p>Each mL of ready-to-use TAKHZYRO solution contains 150 mg of lanadelumab-flyo, citric acid monohydrate (4.1 mg), L-histidine (7.8 mg), polysorbate 80 (0.1 mg), sodium chloride (5.3 mg), sodium phosphate dibasic dihydrate (5.3 mg), and Water for Injection, USP. The solution has a pH of approximately 6.0.</p></section>

TAKHZYRO

lanadelumab-flyo

lanadelumab

2 ML lanadelumab-flyo 150 MG/ML Injection

Takhzyro

2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro]

2 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe

2 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro]

1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe

1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Takhzyro is a monoclonal antibody that controls an overactive enzyme in individuals with hereditary angioedema, a rare genetic immune system disorder. It is prescribed to prevent angioedema attacks in patients aged 2 and above.

Hereditary angioedema leads to elevated bradykinin levels. Takhzyro (lanadelumab-flyo) effectively reduces bradykinin levels, mitigating swelling and associated angioedema symptoms.

Takhzyro injections are FDA-approved for patients aged 2 and older to prevent hereditary angioedema attacks.

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Formulary Exception Letter

Letter of Medical Necessity

Letter of Intent to Treat

Claim Denial Letter

Enroll in Patient Savings Program

Quick Start Program 

One Path Start Form 

Other HCP Resources 

Takhzyro Brochure - English

Takhzyro Brochure - Spanish 

Getting Started Brochure - English

Getting Started Brochure - Spanish

Takhzyro Travel Tips Brochure

Takhzyro Caregiver Brochure

HAE Attack Plan

Caregiver Resources

Doctor Discussion Guide 

About Takhzyro

Side Effects

Injection Training Materials

Taking Takhzyro

Dosing Reminders

Patient Stories

Takhzyro For Children 

Instructions For Use: HAE 

Instructions For Use (Spanish): HAE

One Path Patient Support 